Victory Capital Management
MDGL icon

Victory Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Victory Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2M Buy
5,961
+125
+2% +$64K ﹤0.01% 1501
2026
Q1 		$3.05M Buy
5,836
+14
+0.2% +$6.69K ﹤0.01% 1486
2025
Q4 		$3.39M Buy
5,822
+59
+1% +$30.1K ﹤0.01% 1443
2025
Q3 		$2.64M Sell
5,763
-2,518
-30% -$939K ﹤0.01% 1531
2025
Q2 		$2.51M Sell
8,281
-60,109
-88% -$17.9M ﹤0.01% 1526
2025
Q1 		$22.7M Sell
68,390
-2,245
-3% -$738K 0.02% 768
2024
Q4 		$21.8M Buy
70,635
+68,343
+2,982% +$19.2M 0.02% 811
2024
Q3 		$486K Buy
2,292
+40
+2% +$10.2K ﹤0.01% 2009
2024
Q2 		$631K Buy
2,252
+124
+6% +$29.5K ﹤0.01% 1904
2024
Q1 		$568K Buy
2,128
+208
+11% +$49K ﹤0.01% 1941
2023
Q4 		$444K Buy
1,920
+499
+35% +$87.3K ﹤0.01% 2027
2023
Q3 		$208K Sell
1,421
-1,293
-48% -$243K ﹤0.01% 2196
2023
Q2 		$627K Sell
2,714
-159
-6% -$43.1K ﹤0.01% 1892
2023
Q1 		$696K Buy
2,873
+1,475
+106% +$402K ﹤0.01% 1873
2022
Q4 		$406K Buy
+1,398
New +$137K ﹤0.01% 2075
2020
Q2 		– Sell
-1,651
Closed -$110K – 2948
2020
Q1 		$110K Sell
1,651
-174
-10% -$14.5K ﹤0.01% 2292
2019
Q4 		$166K Buy
1,825
+354
+24% +$34.3K ﹤0.01% 2365
2019
Q3 		$127K Buy
+1,471
New +$138K ﹤0.01% 2364
2019
Q2 		– Sell
-19,885
Closed -$2.49M – 1850
2019
Q1 		$2.49M Buy
19,885
+6,870
+53% +$854K 0.01% 1044
2018
Q4 		$1.47M Sell
13,015
-180,683
-93% -$28M ﹤0.01% 1113
2018
Q3 		$41.5M Buy
193,698
+9,451
+5% +$2.37M 0.09% 396
2018
Q2 		$51.5M Sell
184,247
-18,735
-9% -$3.29M 0.11% 293
2018
Q1 		$23.7M Sell
202,982
-1,224
-0.6% -$151K 0.05% 545
2017
Q4 		$18.7M Buy
204,206
+153,650
+304% +$8.78M 0.04% 595
2017
Q3 		$2.27M Buy
+50,556
New +$946K 0.01% 950

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management's MDGL Position: Q2 2026 in Review

Victory Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 2.1% in Q2 2026, buying an estimated $64K and bringing the position to 5,961 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1501.

Victory Capital Management first reported a position in MDGL in Q3 2017 and has held it in 25 quarters since. The position peaked at $51.5M in Q2 2018. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Victory Capital Management held 5,961 shares of Madrigal Pharmaceuticals worth $3.2M as of Q2 2026.
  • Victory Capital Management bought 125 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $64K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1501 holding.
  • Victory Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • Victory Capital Management's Madrigal Pharmaceuticals position peaked at $51.5M in Q2 2018.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.